The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Age-related macular ... degeneration, comparable to normal mice. This demonstrated that peptide-based eye drops could effectively replace existing injectable therapies for dry AMD. This new ...

The research team from the Natural Product Drug Development Center at the Korea Institute of Science and Technology has developed a new therapeutic agent for dry Age-related macular degeneration that ...

When this support layer fails, it causes macular degeneration and blindness. Doctors have devised a way of building a new retinal pigment epithelium and surgically implanting it into the eye.

In 2003 his right eye developed wet age-related macular degeneration ... was one of five chosen for a clinical trial of Lucentis, a new drug just approved by the FDA to treat the wet form of ...

Sufferers of a degenerative eye disease have been offered hope after a new link between a protein ... levels of a protein factor in age-related macular degeneration (AMD) patients.

Now, a research team at The Ohio State University Wexner Medical Center is studying how the immune system’s inflammatory response can play a role in the development of age-related macular degeneration ...

Around 10 to 15 percent of people with dry AMD develop wet macular degeneration, according to the Macular Society. Wet AMD is ...

the New York City-based company introduced SolidddVision smart glasses. Soliddd claims these are “the first true vision correction for people living with vision loss due to macular degeneration.” ...

More than 2 million Americans suffer from age-related macular degeneration, a leading cause of impaired eyesight in older adults. Damage to the macula, at the center of the retina, leads to blurred or ...